Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia

Despite the successes achieved with molecular targeted inhibition of the oncogenic driver Bcr-Abl in chronic myeloid leukemia (CML), the majority of patients still require lifelong tyrosine kinase inhibitor (TKI) therapy. This is primarily caused by resisting leukemic stem cells (LSCs), which preven...

Descripción completa

Detalles Bibliográficos
Autores principales: Parting, Oliver, Langer, Samantha, Kuepper, Maja Kim, Wessling, Caroline, Li, Shaoguang, Braunschweig, Till, Chatain, Nicolas, Maié, Tiago, Costa, Ivan G., Crysandt, Martina, Huber, Michael, Brümmendorf, Tim H., Koschmieder, Steffen, Schemionek, Mirle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515845/
https://www.ncbi.nlm.nih.gov/pubmed/32684632
http://dx.doi.org/10.1038/s41375-020-0977-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515845/
https://www.ncbi.nlm.nih.gov/pubmed/32684632
http://dx.doi.org/10.1038/s41375-020-0977-8

Ejemplares similares